Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

652

Participants

Timeline

Start Date

June 14, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Moderate to Severe Atopic Dermatitis

Interventions

DRUG

SHR-1819

SHR-1819 injection

DRUG

Placebo

placebo

Trial Locations (1)

Shanghai Fudan University HuaShan Hospital, Shanghai

All Listed Sponsors

lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY

NCT06468956 - Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter